RCM
LXRX icon

Rotella Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Rotella Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-28,583
Closed -$380K – 150
2015
Q4 		$380K Buy
+28,583
New +$351K 0.34% 157
2014
Q4 		– Sell
-1,943
Closed -$19K – 407
2014
Q3 		$19K Buy
+1,943
New +$20.7K 0.02% 299

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Rotella Capital Management's LXRX Position: Q1 2016 in Review

Rotella Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2016, closing a stake of 28,583 shares — an estimated $380K sold.

Rotella Capital Management first reported a position in LXRX in Q3 2014 and held it in 2 quarters. The position peaked at $380K in Q4 2015. 132 funds tracked by Wall St. Rank hold LXRX as of Q1 2016.

  • Rotella Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Rotella Capital Management sold 28,583 Lexicon Pharmaceuticals shares in Q1 2016, an estimated $380K.
  • Rotella Capital Management first reported a position in Lexicon Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • Rotella Capital Management's Lexicon Pharmaceuticals position peaked at $380K in Q4 2015.
  • 132 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2016.

Based on Rotella Capital Management's 13F filing for Q1 2016, filed 13 May 2016.